


Rasarin

Cat. No.:	HY-139950		
CAS No.:	674359-73-0		
Molecular Formula:	C ₂₃ H ₂₄ ClN ₃ O ₃		
Molecular Weight:	425.91		
Target:	Ras		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (117.40 mM; ultrasonic and warming and heat to 60°C)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.3479 mL	11.7396 mL	23.4791 mL
		5 mM	0.4696 mL	2.3479 mL	4.6958 mL
		10 mM	0.2348 mL	1.1740 mL	2.3479 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.87 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.88 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Rasarin is a dual Ras and ARF6 inhibitor ^[1] .
In Vitro	<p>Rasarin potently inhibits agonist-induced ERK1/2 signaling by GPCRs, and MAPK and Akt signaling by EGFR, as well as prevents cancer cell proliferation^[1].</p> <p>?Rasarin blocks GPCR internalization through inhibition of ARF6^[1].</p> <p>?Rasarin treatment results in a dose-dependent reduction in MDA-MB-231 cells^[1].</p> <p>?Rasarin inhibits the recruitment of the clathrin adaptor AP-2 to β-arrestin2 and receptor internalization, both processes that require active ARF6^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

[1]. Jenna Giubilaro, et al. Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen. Nat Commun. 2021 Aug 3;12(1):4688.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA